New psoriasis drug shows promise in Head-to-Head trial against stelara
NCT ID NCT05335356
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 34 times
Summary
This study tested whether a new drug called Bmab 1200 works as well as the approved drug Stelara for adults with moderate to severe plaque psoriasis. 384 participants received either Bmab 1200 or Stelara, and researchers measured skin clearance using the Psoriasis Area and Severity Index (PASI) at 12 weeks. The goal was to see if Bmab 1200 is a safe and effective alternative for controlling this chronic skin condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Apex Clinical Research Center
Mayfield Heights, Ohio, 44124, United States
Conditions
Explore the condition pages connected to this study.